Sangamo gives another update on early-stage Fabry program, enters trial expansion phase
As Sangamo and Pfizer restart dosing on their Phase III hemophilia A program, Sangamo is also ticking off much earlier-stage benchmarks on its Fabry …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
